With the
common effort of the staff scientists and researchers, Creative Biolabs released
its Single Protein Production (SPP) TM technology into the protein production market.
This service is developed mainly for the
R&D of high-throughput protein production.
In the SPP system, live E. coli cells are converted into a
bioreactor producing only a single protein of interest in a high yield. A yield
of 20–30% of total cellular protein can be obtained with our technology, which
overwhelms all protein production methods known so far.
Its technology involves the introduction of an mRNA
endoribonuclease or interferase in E. coli cells to disrupt the endogenous
protein production. However, the cells retain full metabolic activity for RNA
and protein synthesis. Therefore, when the mRNA for a protein of interest is
engineered to be devoid of the mRNA endoribonuclease recognizing sequence
without altering the amino acid sequence of the protein, the cells start to
produce any single protein of your choice.
With the evolution of this technology, Creative Biolabs is now
capable of producing any proteins with the SPP system. With the technology,
protein yields can be kept without being affected even if the culture is
condensed up to 40-folds, reducing the cost of protein production by up to
97.5%. The technology provides isotope-labeled proteins at a very high
signal-to-noise ratio. More than 90% of the isotope can be incorporated into
the target protein in the SPP system. Furthermore, a refinement of this technology
has eliminated lengthy purification steps in the production of membrane
proteins suitable for structural studies.
Learn more about Single
Protein Production (SPP) TM technology of Creative Biolabs.
About Creative Biolabs
Creative Biolabs, a US biotech company established in 2005, is
focused on the research and development of antibody engineering and protein
production. Learn more about Creative
Biolabs.
